Pfizer's Strong Quarter Secures VanEck Dividend ETF Spot as €2.1bn Inflow Wave Triggers Overbought Signal

Pfizer’s strong Q1 earnings secure its top position in TDIV ETF; the fund attracts €2.1bn in record dividend inflows, with a five-star Morningstar rating and overbought RSI.

Pfizer’s first-quarter revenue of $14.45bn comfortably beat expectations, and management reaffirmed its full-year guidance. For the VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF (TDIV), that performance was enough to lock in the pharmaceutical giant’s position as the fund’s second-largest holding ahead of a critical index review in June.

The ETF applies two hard screens to every candidate stock. The current dividend must be no lower than five years ago, and the payout ratio cannot exceed 75% of earnings. Pfizer cleared both hurdles, joining a portfolio that is heavily tilted toward financials (31%), energy and healthcare. Other top weights include Exxon Mobil, Verizon and TotalEnergies.

Investor Rotation Fuels Record Quarter

The fund’s defensive profile has proved magnetic in a market that is rotating away from expensive tech stocks. Worldwide, dividend-focused funds attracted roughly $24bn in the first quarter of 2026 – the strongest inflow in four years – and TDIV alone collected €2.1bn of that sum. The ETF now sits at €7.6bn in assets under management.

Supporting the rotation is a macro backdrop that benefits the fund’s largest sector. The European Central Bank has held its deposit rate at 2.0%, while euro-area inflation climbed to 3.0% in March. European banks have leveraged that spread to boost earnings, strengthening the foundation for the dividends that TDIV tracks.

Five-Star Rating and a Hot RSI

Morningstar awarded the fund its highest five-star rating in early May, citing a five-year annualised return of 17.9% – more than double the category average of roughly 8%. The ETF’s expense ratio of 0.38% is a fraction of the peer median, helping to explain the persistent net flows.

But that strong performance has pushed the shares into overbought territory. TDIV last traded at €52.50, just a whisker below its 52-week high set in late April, with a relative strength index just above 74. Any near-term pullback would partly relieve that technical pressure, though the fund’s long-term uptrend remains intact.

New Accumulating Sibling Launches

Until recently, TDIV’s Dutch domicile prevented the creation of an accumulating share class without triggering tax drawbacks for existing investors. VanEck solved the puzzle in late April by launching a sister fund, TDVX, domiciled in Ireland and listed in Frankfurt and London.

TDVX follows the same index methodology but excludes US stocks entirely. Its automatic reinvestment feature appeals to investors who want to compound dividends without manual intervention. The timing also suits the current climate: international markets outside the US have outpaced the S&P 500 of late, making TDVX’s non?US focus a natural fit.

What June Holds

June will be a pivotal month for the main fund. The semi-annual index rebalancing will determine which of the 100 positions stay in the portfolio and which must exit to maintain the strict dividend and payout filters. At the same time, the ETF’s regular distribution is due, adding another event for income?focused shareholders.

With the RSI flashing caution and a busy calendar ahead, TDIV enters the second half of 2026 with both momentum and a set of catalysts that could either extend its run or test its recent highs.